Novavax (NASDAQ:NVAX) was on track to end its seventh consecutive session in the red territory after shares of the company declined 1.73% to $6.54 on Friday afternoon. The vaccine maker lost close to ...

Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine. • NVAX stock is showing ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Gaithersburg company ...

Novavax, Inc. receives a Hold rating, reflecting improved prospects after its Sanofi partnership and upgraded 2025 revenue guidance to $1–1.05 billion. The SNY deal provides upfront payments, ...

Novavax (NASDAQ:NVAX) traded higher in the premarket on Wednesday after the Maryland-based biotech reported better-than-expected Q2 financials and raised its 2025 revenue outlook, citing, among other ...

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Novavax ( (NVAX)) has issued an update.

(RTTNews) - Novavax, Inc. (NVAX) announced Tuesday progress on its collaboration and license agreement (CLA) with Sanofi SA (SNY) regarding Novavax's Matrix-M adjuvant. The companies have amended ...

NEW YORK -- The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the ...

Novavax, Inc. (NASDAQ:NVAX) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company’s non-mRNA COVID-19 vaccine is approved, strengthening its Sanofi partnership. Novavax, Inc. (NASDAQ:NVAX ...

Nov 30 (Reuters) - Novavax Inc (NVAX.O), opens new tab on Monday pushed back the start of a U.S.-based, late-stage trial for its experimental COVID-19 vaccine for the second time and now expects it to ...